Pacific Edge Limited, a global leader in cancer diagnostics, has published its Annual Report for the year ending 31 March 2025. The report highlights the company's resilient performance amid uncertainties surrounding Medicare coverage, showcasing improvements in sales force performance, operating efficiencies, and cash collection. These advancements position Pacific Edge for accelerated growth as it aims to regain Medicare coverage for its diagnostic tests. The company continues to develop and commercialize bladder cancer diagnostic and prognostic tests, maintaining its commitment to operational quality and compliance. The full report can be accessed through the link below.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。